5 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 8 Phase 2, 5 Phase 1, 3 Phase 3, 1 Not applicable.
Follow Fluorouracil (5-FU): new trials by email Literature Review of Fluorouracil (5-FU) trials Research Report on Fluorouracil (5-FU)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carbon Dioxide Laser-Assisted Delivery of Triamcinolone With or Without 5-Fluorouracil for Hypertrophic Burn Scars Fractional Ablative CO₂ Laser, Triamcinolone Acetonide, Fluorouracil (5-FU) - Burn, Hypertrophic Scars | Not applicable | Not yet recruiting | University of California, Davis | 65 | 2026-08-22 | 2026-08-24 |
| An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma Pembrolizumab, Docetaxel, Oxaliplatin - Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center Hospital East | 26 | 2025-07-24 | 2025-08-26 |
| FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. Atezolizumab, Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 238 | 2024-11-15 | 2025-12-08 |
| M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) M9466, Irinotecan, Folinic acid - Advanced Solid Tumor | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2024-10-08 | 2025-12-18 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-20 |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) Fluorouracil (5-FU), Capecitabine, Durvalumab - Gastric Cancer | Phase 2 | Active not recruiting | AstraZeneca | 452 | 2020-06-03 | 2026-08-28 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes) - Urinary Bladder Neoplasms | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 520 | 2020-05-19 | 2026-05-01 |
| A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Cisplatin, Oxaliplatin, Fluorouracil (5-FU) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Completed | BeiGene | 649 | 2018-12-11 | 2025-07-29 |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Sym004, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Symphogen A/S | 10 | 2016-03-15 | 2019-03-26 |
| A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC Recombinant Human Endostatin Injection (Endostar), Fluorouracil (5-Fu), Nedaplatin - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Yun-fei Xia | 328 | 2015-07-01 | 2017-12-22 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC) - Metastatic Colorectal Cancer | Phase 2 | Completed | Symphogen A/S | 254 | 2014-03-06 | 2019-04-16 |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer BKM120, mFOLFOX6 - Advanced Solid Tumors, Metastatic Colorectal Cancer | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 17 | 2012-05-01 | 2017-04-26 |
| Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer REOLYSIN®, Irinotecan, Leucovorin - KRAS Mutant Metastatic Colorectal Cancer | Phase 1 | Completed | Oncolytics Biotech | 36 | 2010-12-01 | 2018-12-19 |
| Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine - Cancer | Phase 2 | Terminated | University of Utah | 1 | 2009-09-01 | 2015-08-19 |
| Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver Floxuridine, Fluorouracil (5-FU), Conventional surgery - Colorectal Cancer, Metastatic Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 1998-08-05 | 2018-10-26 |
Colorectal Neoplasms (6) · Adenocarcinoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Biliary Tract Neoplasms (1) · Burns (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Cicatrix, Hypertrophic (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Liver Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Pancreatic Neoplasms (1)
Merck Sharp & Dohme LLC (2) · Symphogen A/S (2) · AstraZeneca (1) · BeiGene (1) · EMD Serono Research & Development Institute, Inc. (1) · Gruppo Oncologico del Nord-Ovest (1) · M.D. Anderson Cancer Center (1) · National Cancer Center Hospital East (1) · Oncolytics Biotech (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, Davis (1) · University of Utah (1) · Yun-fei Xia (1)
United States (11) · Spain (7) · Italy (6) · Japan (6) · South Korea (5) · Australia (4) · China (4) · Poland (4) · Taiwan (4) · United Kingdom (4) · France (3) · Germany (3) · Russia (3) · Belgium (2) · Canada (2)
Josep Tabernero, MD, PhD (2) · Autumn McRee, MD (1) · Carlotta Antoniotti, MD, PhD (1) · Christopher Anker, MD (1) · Ian A Powelson, MD (1) · Lee M. Ellis, MD (1) · Yun-fei Xia, Prof (1)
PMID 37080222, PMID 40075024, PMID 40341124, PMID 40373876, PMID 42834033
2019 (2), 2023 (2), 2015 (1), 2018 (1), P30CA016672 (1)